Doyun Park1, William Southern2, Manuela Calvo2, Margarita Kushnir3, Clemencia Solorzano4, Mark Sinnet4, Henny H Billett3. 1. Division of Hematology-Oncology, Mount Sinai-Roosevelt Hospital, 1000 Tenth Avenue, New York, NY, USA. dpark@chpnet.org. 2. Division of Hospital Medicine, Department of Medicine, Montefiore Medical Center of Albert Einstein College of Medicine, Bronx, NY, USA. 3. Division of Hematology, Department of Oncology, Montefiore Medical Center of the Albert Einstein College of Medicine, Bronx, NY, USA. 4. Department of Pharmacy, Montefiore Medical Center, Bronx, NY, USA.
Abstract
BACKGROUND: Low molecular weight heparins (LMWHs) have been cautiously used in patients with chronic kidney disease (CKD) due to fear of accumulation. Dalteparin, however, has shown minimal tendency to accumulate in patients with CKD and may be safe to use in this patient population. OBJECTIVE: We compared the incidence of clinically significant bleeding in patients with CKD receiving therapeutic doses of dalteparin to that of patients with CKD receiving therapeutic doses of UFH. DESIGN: This was a retrospective cohort study. SUBJECTS: Inpatients with CKD (GFR < 60 ml/min) who were treated with therapeutic dalteparin or UFH were included in the study MAIN MEASURES: Primary outcome was major bleeding within 10 days of anticoagulation, identified by ICD-9 code and confirmed by chart review. Demographic characteristics, laboratory values, comorbidities, prior bleeding history and inpatient medications were extracted for each admission from the electronic medical record. Logistic regression models were created to examine the association between choice of anticoagulant and bleeding rates, after adjustment for demographic and clinical characteristics. KEY RESULTS: Dalteparin-treated patients were significantly less likely to experience a major bleed than patients treated with UFH (1.14 % vs. 3.49 %, p < 0.001). The reduced likelihood of bleeding associated with dalteparin treatment remained significant after adjustment for patient characteristics (HR 0.39, 95 % CI: 0.21-0.70, p < 0.0001). A stratified analysis for subgroups with GFR< 30 mL/min and with GFR between 30 and 60 mL/min showed that dalteparin was still associated with lower odds of bleeding compared to treatment with unfractionated heparin, but the difference was nonsignificant for GFR< 30 (HR 0.35, 95 % CI: 0.11-1.15), even after adjustment (OR 0.37, 95 % CI: 0.11-1.22). CONCLUSION: In patients with CKD, treatment with therapeutic dose dalteparin was associated with lower rates of bleeding than treatment with unfractionated heparin. For patients with severe CKD (GFR< 30), dalteparin was shown to be at least as safe as unfractionated heparin.
BACKGROUND: Low molecular weight heparins (LMWHs) have been cautiously used in patients with chronic kidney disease (CKD) due to fear of accumulation. Dalteparin, however, has shown minimal tendency to accumulate in patients with CKD and may be safe to use in this patient population. OBJECTIVE: We compared the incidence of clinically significant bleeding in patients with CKD receiving therapeutic doses of dalteparin to that of patients with CKD receiving therapeutic doses of UFH. DESIGN: This was a retrospective cohort study. SUBJECTS: Inpatients with CKD (GFR < 60 ml/min) who were treated with therapeutic dalteparin or UFH were included in the study MAIN MEASURES: Primary outcome was major bleeding within 10 days of anticoagulation, identified by ICD-9 code and confirmed by chart review. Demographic characteristics, laboratory values, comorbidities, prior bleeding history and inpatient medications were extracted for each admission from the electronic medical record. Logistic regression models were created to examine the association between choice of anticoagulant and bleeding rates, after adjustment for demographic and clinical characteristics. KEY RESULTS:Dalteparin-treated patients were significantly less likely to experience a major bleed than patients treated with UFH (1.14 % vs. 3.49 %, p < 0.001). The reduced likelihood of bleeding associated with dalteparin treatment remained significant after adjustment for patient characteristics (HR 0.39, 95 % CI: 0.21-0.70, p < 0.0001). A stratified analysis for subgroups with GFR< 30 mL/min and with GFR between 30 and 60 mL/min showed that dalteparin was still associated with lower odds of bleeding compared to treatment with unfractionated heparin, but the difference was nonsignificant for GFR< 30 (HR 0.35, 95 % CI: 0.11-1.15), even after adjustment (OR 0.37, 95 % CI: 0.11-1.22). CONCLUSION: In patients with CKD, treatment with therapeutic dose dalteparin was associated with lower rates of bleeding than treatment with unfractionated heparin. For patients with severe CKD (GFR< 30), dalteparin was shown to be at least as safe as unfractionated heparin.
Authors: Enrico Tincani; Caterina Mannucci; Barbara Casolari; Fabrizio Turrini; Mark A Crowther; Domenico Prisco; Anna Maria Cenci; Marco Bondi Journal: Haematologica Date: 2006-06-01 Impact factor: 9.941
Authors: Adam R Shprecher; Angela Cheng-Lai; Eileen M Madsen; Hillel W Cohen; Mark J Sinnett; Serena T Wong; Henny H Billett Journal: Pharmacotherapy Date: 2005-06 Impact factor: 4.705
Authors: Javier Trujillo-Santos; Sebastian Schellong; Conxita Falga; Vanessa Zorrilla; Pedro Gallego; Manuel Barrón; Manuel Monreal Journal: Am J Med Date: 2013-03-14 Impact factor: 4.965
Authors: Douglas D DeCarolis; Joey G Thorson; Megan A Clairmont; Amy M Leuthner; Thomas S Rector; Gerhard J Johnson Journal: Arch Intern Med Date: 2012-12-10
Authors: Cecilia Becattini; Rupert Bauersachs; Giorgio Maraziti; Laurent Bertoletti; Alexander Cohen; Jean M Connors; Dario Manfellotto; Antonio Sanchez; Benjamin Brenner; Giancarlo Agnelli Journal: Haematologica Date: 2022-07-01 Impact factor: 11.047